X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cipla with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs TEVA PHARMA (Israel) - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   TEVA PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-18
TEVA PHARMA
Dec-13
CIPLA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6632,977-   
Low Rs4792,586-   
Sales per share (Unadj.) Rs189.01,708.7-  
Earnings per share (Unadj.) Rs17.6106.7-  
Cash flow per share (Unadj.) Rs34.0244.9-  
Dividends per share (Unadj.) Rs3.0093.44-  
Dividend yield (eoy) %0.53.4 15.6%  
Book value per share (Unadj.) Rs176.71,898.1-  
Shares outstanding (eoy) m805.12848.00-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.6 185.5%   
Avg P/E ratio x32.526.1 124.5%  
P/CF ratio (eoy) x16.811.4 147.7%  
Price / Book Value ratio x3.21.5 220.4%  
Dividend payout %17.187.5 19.5%   
Avg Mkt Cap Rs m459,7242,359,026 19.5%   
No. of employees `00023.644.9 52.5%   
Total wages/salary Rs m26,9010-   
Avg. sales/employee Rs Th6,446.132,239.4 20.0%   
Avg. wages/employee Rs Th1,139.40-   
Avg. net profit/employee Rs Th600.02,014.0 29.8%   
INCOME DATA
Net Sales Rs m152,1931,448,998 10.5%  
Other income Rs m3,5770-   
Total revenues Rs m155,7691,448,998 10.8%   
Gross profit Rs m28,264396,809 7.1%  
Depreciation Rs m13,228117,124 11.3%   
Interest Rs m1,14228,461 4.0%   
Profit before tax Rs m17,470251,224 7.0%   
Minority Interest Rs m01,141 0.0%   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-775-164,915 0.5%   
Tax Rs m2,501-3,067 -81.5%   
Profit after tax Rs m14,16690,518 15.6%  
Gross profit margin %18.627.4 67.8%  
Effective tax rate %14.3-1.2 -1,172.6%   
Net profit margin %9.36.2 149.0%  
BALANCE SHEET DATA
Current assets Rs m108,141978,648 11.1%   
Current liabilities Rs m38,322853,463 4.5%   
Net working cap to sales %45.98.6 531.0%  
Current ratio x2.81.1 246.1%  
Inventory Days Days9791 106.8%  
Debtors Days Days7496 77.6%  
Net fixed assets Rs m109,411473,275 23.1%   
Share capital Rs m1,6103,567 45.1%   
"Free" reserves Rs m140,6820-   
Net worth Rs m142,2921,609,561 8.8%   
Long term debt Rs m36,621740,905 4.9%   
Total assets Rs m228,6063,311,424 6.9%  
Interest coverage x16.39.8 165.8%   
Debt to equity ratio x0.30.5 55.9%  
Sales to assets ratio x0.70.4 152.1%   
Return on assets %6.73.6 186.4%  
Return on equity %10.05.6 177.0%  
Return on capital %10.04.9 201.8%  
Exports to sales %32.80-   
Imports to sales %00-   
Net fx Rs m30,6580-   
CASH FLOW
From Operations Rs m14,628230,895 6.3%  
From Investments Rs m-8,540-81,816 10.4%  
From Financial Activity Rs m-3,855-276,974 1.4%  
Net Cashflow Rs m2,431-127,895 -1.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 71.33 Rs / USD

Compare CIPLA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare CIPLA With: ORCHID PHARMA LTD  IPCA LABS  DIVIS LABORATORIES  LUPIN LTD  DR. REDDYS LAB  



Today's Market

Sensex Ends Marginally Higher; Healthcare and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued to trade near the dotted line during closing hours and ended the day marginally higher. Gains were largely seen in the healthcare sector .

Related Views On News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

More Views on News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

Follow a Super Investor Like This to Multiply Your Wealth(The 5 Minute Wrapup)

Jan 4, 2019

Following a super investor can certainly help build a portfolio and create wealth in the long term.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

HDFC Bank Still Going Strong(Chart Of The Day)

Jan 4, 2019

The stock of HDFC Bank has continued to reward shareholders.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 17, 2019 (Close)

TRACK CIPLA

CIPLA - LUPIN LTD COMPARISON

COMPARE CIPLA WITH

MARKET STATS